List of Arazlo drug patents
Arazlo is owned by Bausch.
Arazlo contains Tazarotene.
Arazlo has a total of 1 drug patent out of which 0 drug patents have expired.
Arazlo was authorised for market use on 18 December, 2019.
Arazlo is available in lotion;topical dosage forms.
Arazlo can be used as topical treatment of acne vulgaris in patients 9 years of age and older.
The generics of Arazlo are possible to be released after 11 May, 2038.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11311482 | BAUSCH | Topical compositions and methods for treating skin diseases |
May, 2038
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Dec 18, 2022 |
Drugs and Companies using TAZAROTENE ingredient
Market Authorisation Date: 18 December, 2019
Treatment: Topical treatment of acne vulgaris in patients 9 years of age and older
Dosage: LOTION;TOPICAL
ARAZLO family patents
13
United States
2
Canada
2
Japan
2
Brazil
2
European Union
1
Portugal
1
Hungary
1
Korea, Republic of
1
Slovenia
1
Croatia
1
Poland
1
Australia
1
RS
1
Denmark
1
Mexico
1
Lithuania
1
Spain
1
China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic